NCT05834244View on ClinicalTrials.gov

A Phase Ib Trial of Azacitidine, Venetoclax and Allogeneic NK Cells for Acute Myeloid Leukemia (ADVENT-AML)

PHASE1RecruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

October 26, 2023

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2028

Conditions
Acute Myeloid Leukemia
Interventions
DRUG

Azacitidine

Given by IV (vein)

DRUG

Venetoclax

Given by PO

DRUG

NK Cells

Given by IV (vein)

Trial Locations (2)

44106

RECRUITING

Case Western Reserve University, Cleveland

77030

RECRUITING

M.D. Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER